首页 | 本学科首页   官方微博 | 高级检索  
检索        

聚乙烯醇颗粒在原发性肝癌经导管肝动脉化疗栓塞术中的应用
引用本文:陈俊伟,朱康顺,孟晓春,何可可,钱结胜,沈敏,黄文薮,单鸿.聚乙烯醇颗粒在原发性肝癌经导管肝动脉化疗栓塞术中的应用[J].中国医学影像技术,2010,26(3):559-562.
作者姓名:陈俊伟  朱康顺  孟晓春  何可可  钱结胜  沈敏  黄文薮  单鸿
作者单位:中山大学附属第三医院放射科,广东,广州,510630
摘    要:目的 探讨聚乙烯醇颗粒(PVA)在原发性肝癌经导管肝动脉化疗栓塞术(TACE)中的应用价值.方法 对20例肝癌患者行TACE术,术中先使用碘化油化疗药物混合乳剂栓塞肿瘤血管,再用PVA颗粒超选择性插管栓塞肿瘤供血动脉.观察患者术后1个月、3个月、6个月、1年时肿瘤缩小程度、治疗有效率及甲胎蛋白(AFP)水平变化;术后1周及1个月时血清天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)及总胆红素(TBILI)水平,记录疾病进展时间及生存期.结果 术后1个月、3个月、6个月、1年肿瘤直径均较术前明显缩小(P<0.05),其治疗有效率(完全缓解+部分缓解)分别为80.00%、90.00%、95.00%、95.00%,AFP水平较术前明显下降(P<0.05).术后1周AST、ALT、TBILI均较术前明显升高(P<0.05),但1个月时AST、ALT、TBILI均恢复为术前水平.随访时间12~32(19.8±7.0)个月,疾病进展时间为(17.0±6.8)个月,总生存时间为(19.3±7.0)个月.结论 PVA颗粒作为永久性栓塞材料,在肝癌TACE中栓塞效果明显,但术中需超选择性插管到肿瘤供血动脉内进行栓塞治疗.

关 键 词:肝肿瘤  经导管肝动脉化疗栓塞术  PVA颗粒  放射学  介入性
收稿时间:2009/8/19 0:00:00
修稿时间:2009/11/26 0:00:00

Transcatheter arterial chemoembolization using polyvinyl alcohol particles in patients with primary hepatic cancer
CHEN Jun-wei,ZHU Kang-shun,MENG Xiao-chun,HE Ke-ke,QIAN Jie-sheng,SHEN Min,HUANG Wen-sou and SHAN Hong.Transcatheter arterial chemoembolization using polyvinyl alcohol particles in patients with primary hepatic cancer[J].Chinese Journal of Medical Imaging Technology,2010,26(3):559-562.
Authors:CHEN Jun-wei  ZHU Kang-shun  MENG Xiao-chun  HE Ke-ke  QIAN Jie-sheng  SHEN Min  HUANG Wen-sou and SHAN Hong
Institution:Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China;Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China;Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China;Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China;Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China;Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China;Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China;Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China
Abstract:Objective To assess the clinical value of transcatheter arterial chemoembolization (TACE) with polyvinyl alcohol (PVA) particles as embolic material in patients with primary hepatic cancer (PHC). Methods Twenty patients with PHC underwent TACE. The mixed emulsion of chemotherapy agents and lipiodol was given to embolize the tumor vssTranscatheter arterial chemoembolization using polyvinyl alcohol feeding artery of tumors. The tumors size, response rate and Alpha-Fetoprotein (AFP) value were monitored respectively at the end of the first month, the third month, the sixth month and the first year after TACE. The changes of liver function, including serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (TBILI), were recorded within 1 week and 1 month after TACE. The time to progression and the overall survival were recorded. Results Compared with pre-TACE, the tumor size decreased obviously at the end of the first month, the third month, the sixth month and the first year after TACE (P<0.05), the response rate reached 80.00%, 90.00%, 95.00% and 95.00%, respectively. The AFP value decreased obviously. Serum AST, ALT and TBILI significantly increased in the first week after TACE (P<0.05), but returned to preoperative level within 1 month. The average follow-up time was (19.8±7.0) months (range 12-32 months), the time to progression was (17.0±6.8) months, and the overall survival was (19.3±7.0) months. Conclusion PVA particles are optimal embolic material for TACE of PHC. Superselective embolization is necessary in TACE to achieve effective tumor devascularization and reduce liver damage.
Keywords:Liver neoplasms  Transcatheter arterial chemoembolization  Polyvinyl alcohol particles  Radiology  interventional
本文献已被 万方数据 等数据库收录!
点击此处可从《中国医学影像技术》浏览原始摘要信息
点击此处可从《中国医学影像技术》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号